. Author manuscript; available in PMC: 2021 Oct 1.

Published in final edited form as: Ann Allergy Asthma Immunol. 2019 Sep 5;125(4):380–387. doi: 10.1016/j.anai.2019.08.465

Table 1:

Therapeutics under investigation in clinical trials for treatment of CSU

Study Drug	Mechanism	Phase	Clinicaltrials.gov identifier
Ligelizumab	Anti-IgE	Phase 3	NCT03580356
AK002	Anti-Siglec-8	Phase 2	NCT03436797
GSK2646264	Topical SYK inhibitor	Phase 1	NCT02424799
Fenebrutinib	BTK inhibitor	Phase 2	NCT03693625
Benralizumab	Anti-IL-5R	Phase 4	NCT03183024
Mepolizumab	Anti-IL-5	Phase 1	NCT03494881
Dupilumab	Anti-IL-4/13	Phase 2	NCT03749135